ONLINE 3D Medical Printing Series
26 January 2021 - 4 February 2021, 12:00 - 16:00 CET (Central European Time)
#3dmedical #3dbio #3dmedtech #3ddental #3dpharma
Rainbow Coral Corp. and Nano3D Biosciences (n3D) are lining up new 3D bioprinting opportunities and potential partnerships following a highly successful product exhibition last month at Biotech Showcase 2015 in San Francisco. Continue reading “Rainbow Coral and Nano3D Biosciences Pursue New 3D Bioprinting Opportunities, Partnerships”
In the U.S. The National Institute of Health has moved a step closer to help to fund the joint venture of Rainbow Coral Corp. and Nano3D Biosciences. Nano3D has been awarded a grant for work associated with its recent proposal Novel 3D high-content/throughput assay with mobile device-based data acquisition. Continue reading “New Funding for Rainbow 3D Bioprinting System That May Replace Animal Toxicity Tests”
As Rainbow Coral Corp. works to market and develop an innovative new 3D bioprinting system, new 3D printing innovations are generating massive new demand for the technology from patients and doctors alike in the medical industry. Continue reading “RBCC: New Innovations Spur Demand for 3D Printing in Medicine”
In the whirlwind of news, inventions and ideas spiralling out of the additive manufacturing/3D printing revolution there is one whose potential is so big that the media have actually been a bit reluctant to talk about it: bioprinting (or bioplotting). Continue reading “Bioprinting Is Booming and Rainbow Biosciences Wants a Piece”
Rainbow Coral Corp. (OTCBB: RBCC) is well-positioned to capitalize on the revolution in medicine being spurred on by 3D printing technology thanks to the innovative BiO Assay, a new 3D bioprinting system developed by RBCC’s joint venture partner, Nano3D Biosciences (n3D). Continue reading “RBCC Moves to the Front Lines of the 3D Bioprinting Revolution”